Regeneron Pharmaceuticals, Inc.
Dupixent
chronic spontaneous urticaria (CSU)
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on Dupixent for chronic spontaneous urticaria (CSU) is expected Date TBD.
Primary source
· SEC 8-K
verified 15h ago
“the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Dupixent for the treatment of adults with moderate-to-severe bullous pemphigoid (BP).”